Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

Boris Engels, Victor H. Engelhard, John Sidney, Alessandro Sette, David C. Binder, Rebecca B. Liu, David M Kranz, Stephen C. Meredith, Donald A. Rowley, Hans Schreiber

Research output: Contribution to journalArticle

Abstract

Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.

Original languageEnglish (US)
Pages (from-to)516-526
Number of pages11
JournalCancer Cell
Volume23
Issue number4
DOIs
StatePublished - Apr 15 2013

Fingerprint

Major Histocompatibility Complex
T-Lymphocytes
Recurrence
Peptides
Neoplasms
Cross-Priming
Immunotherapy
Cytokines
Antigens
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Engels, B., Engelhard, V. H., Sidney, J., Sette, A., Binder, D. C., Liu, R. B., ... Schreiber, H. (2013). Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell, 23(4), 516-526. https://doi.org/10.1016/j.ccr.2013.03.018

Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. / Engels, Boris; Engelhard, Victor H.; Sidney, John; Sette, Alessandro; Binder, David C.; Liu, Rebecca B.; Kranz, David M; Meredith, Stephen C.; Rowley, Donald A.; Schreiber, Hans.

In: Cancer Cell, Vol. 23, No. 4, 15.04.2013, p. 516-526.

Research output: Contribution to journalArticle

Engels, B, Engelhard, VH, Sidney, J, Sette, A, Binder, DC, Liu, RB, Kranz, DM, Meredith, SC, Rowley, DA & Schreiber, H 2013, 'Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity', Cancer Cell, vol. 23, no. 4, pp. 516-526. https://doi.org/10.1016/j.ccr.2013.03.018
Engels, Boris ; Engelhard, Victor H. ; Sidney, John ; Sette, Alessandro ; Binder, David C. ; Liu, Rebecca B. ; Kranz, David M ; Meredith, Stephen C. ; Rowley, Donald A. ; Schreiber, Hans. / Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. In: Cancer Cell. 2013 ; Vol. 23, No. 4. pp. 516-526.
@article{4b7d603385db4265b9ba4232f53aeb51,
title = "Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity",
abstract = "Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.",
author = "Boris Engels and Engelhard, {Victor H.} and John Sidney and Alessandro Sette and Binder, {David C.} and Liu, {Rebecca B.} and Kranz, {David M} and Meredith, {Stephen C.} and Rowley, {Donald A.} and Hans Schreiber",
year = "2013",
month = "4",
day = "15",
doi = "10.1016/j.ccr.2013.03.018",
language = "English (US)",
volume = "23",
pages = "516--526",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

AU - Engels, Boris

AU - Engelhard, Victor H.

AU - Sidney, John

AU - Sette, Alessandro

AU - Binder, David C.

AU - Liu, Rebecca B.

AU - Kranz, David M

AU - Meredith, Stephen C.

AU - Rowley, Donald A.

AU - Schreiber, Hans

PY - 2013/4/15

Y1 - 2013/4/15

N2 - Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.

AB - Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84876381248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876381248&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2013.03.018

DO - 10.1016/j.ccr.2013.03.018

M3 - Article

C2 - 23597565

AN - SCOPUS:84876381248

VL - 23

SP - 516

EP - 526

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -